CSIMarket


Summit Therapeutics Inc   (SMMT)
Other Ticker:  
 


 

Summit Therapeutics Inc

SMMT's Financial Statements and Analysis



Summit Therapeutics Inc narrowed forth quarter of 2023 net loss per share of $-0.03 compare to net loss per share of $-0.04 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.03 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.03 $  0 Mill
$+0.01     Unch.    



Summit Therapeutics Inc 's Revenue fell by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Summit Therapeutics Inc is

More on SMMT's Income Statement



Summit Therapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-36.567 million, an increase from net loss of $-19.229 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on SMMT's Growth

Summit Therapeutics Inc Inventories
SMMT's Cash flow In the forth quarter of 2023 company's net cash flow was $48 million

More on SMMT's Cash flow Statement


Summit Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Summit Therapeutics Inc payed $ -0.12 cash per share, on a free-cash flow basis .

Book value fell by -12.18 % sequentially to $0.13 per share, -1.15% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.12 per share from $ 0.14.

Company repurchased 76.60 million shares or 10.98 % in Dec 31 2023.


More on SMMT's Dividends

 Market Capitalization (Millions) 2,323
 Shares Outstanding (Millions) 621
 Total Debt (Millions $) 100
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -615
 Cash Flow (TTM) (Millions $) -577
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 70




Summit Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Summit Therapeutics Inc had negative $ -0.12 cash flow per share, on a free-cash flow basis .

Book value fell by -12.18 % sequentially to $0.13 per share, -1.15% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.12 per share from $ 0.14.

Company repurchased 76.60 million shares or 10.98 % in Dec 31 2023.


More on SMMT's Balance Sheets

 Market Capitalization (Millions) 2,323
 Shares Outstanding (Millions) 621
 Total Debt (Millions $) 100
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -615
 Cash Flow (TTM) (Millions $) -577
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 70
   


  News about Summit Therapeutics Inc Earnings

2. Summit Therapeutics Inc. Shows Promise with Innovative Ivonescimab Drug in Financial Fourth Quarter of 2023

Miami, FL - Summit Therapeutics Inc. (NASDAQ: SMMT) recently reported its financial results for the fourth quarter and year-ended December 31, 2023. The innovative healthcare company, known for its groundbreaking clinical programs aimed at providing new treatment options for patients with infectious diseases, also provided updates on its operational progress. These updates were presented at the 42nd Annual J.P. Morgan Healthcare Conference, held in San Francisco, CA.
One of the key highlights of the updates is the progress of Ivonescimab (SMT112), an investigational bispecific antibody that combines the effects of immunotherapy with anti-angiogenesis. Ivonescimab has the potential to become a first-in-cl...

Third Quarter of 2023 Showcases Resilient Revenue for Major Pharmaceutical Preparations Companies

Over the past five days, shares of Summit Therapeutics Inc (NASDAQ: SMMT) have experienced a decline of -2.05%. This drop adds to the company's year-to-date performance, which is currently at -61.8%. Furthermore, the shares are currently trading on the NASDAQ at -10.8% below their 52-week average.
For the fiscal period ending on September 30, 2023, Summit Therapeutics Inc reported a loss of $-0.03 per share. This is an improvement compared to the loss of $-0.14 per share from the previous year, but a slight increase from the loss of $-0.02 per share from the prior reporting season. The revenue for this period remained unchanged at $0.00 million, compared to $0.22 million in the same reporting season the ...

Summit Therapeutics Inc Successfully Narrows Loss per Share, Demonstrating Upgraded Financial Performance in Q2 2023



Summit Therapeutics Inc, a prominent pharmaceutical company, recently released its financial results for the period between April and June 30, 2023. The figures exhibit a significant reduction in the loss per share, improved earnings per share, and stable revenues compared to the previous year. These results have sparked curiosity and speculation about how they will shape the future of the company.
Improved Financials:
1. Substantial Decrease in Loss per Share: Summit Therapeutics Inc managed to decrease its loss per share from $-0.17 in the same reporting season last year to $-0.02. This considerable reduction indicates a positive trend in the company's financial performance and signifies ...

Summit Therapeutics Inc reports substantial loss and lackluster revenue in Q1 2023

Investors in Summit Therapeutics Inc have reason to be cautious after the company reported a substantial loss in the first quarter of 2023. The loss per share stood at $-1.43 per share, a significant increase from the $-0.22 per share reported in the same period a year prior. Furthermore, the loss for the current reporting period grew to $-0.04 per share. Investors will also note that revenue remained flat and unaffected at $0.00 million, compared to $0.25 million in the same reporting period last year and sequentially from $0.00 million.
Looking at the overall performance of Summit Therapeutics Inc, investors will be concerned about the significant increase in net losses, which stood at $-542.376 millio...


Date modified: 2024-02-20T15:53:48+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com